Overview

AXP107-11 in Combination With Standard Gemcitabine (Gemzar® ) Therapy for Treatment in Patients With Pancreatic Cancer

Status:
Unknown status

Trial end date:
2016-03-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the effect and safety of AXP107-11 alone, and in combination with gemcitabine standard therapy, in patients with advanced or metastatic cancer of the pancreas. The safety, pharmacokinetics and efficacy of AXP107-11 in these patients will also be studied.

Phase:

Phase 1/Phase 2

Details

Lead Sponsor:

Axcentua Pharmaceuticals AB

Treatments:

Gemcitabine
Genistein